Mark H. Einstein, MD, MS
Professor and Chair, Department of Obstetrics, Gynecology, & Women’s Health
Assistant Dean, Clinical Research Unit at Rutgers New Jersey Medical School.
Dr. Einstein’s primary research interests focus on the pathogenesis, therapy, and prevention of cervical cancer. He has been funded for many efforts identifying unique, potentially drugeable, targets and biomarkers for clinical risk of malignant transformation. Dr. Einstein has developed and has been leading numerous multi-institutional clinical trials in targeting HPV and cervical cancer as well as cervical cancer prevention. He is active in clinical trial cooperative groups as Co-Chair of NRG Oncology (formerly the Gynecologic Oncology Group) Immunotherapy Subcommittee and a voting member of the NRG Cancer Prevention and Control Committee, as well as a prior member of the NRG Cervix Committee. He is on the HPV working group of the NCI Aids Malignancy Consortium and leads their Cervical Cancer efforts in the setting of HIV. He has been active in translating clinical trial and translational data into clinical practices regarding cervical cancer prevention including being a 1) member of the Steering Committee for the American Society for Colposcopy and Cervical Pathology (ASCCP) Cervical Screening and Management Guidelines, 2) workgroup member of the American Cancer Society and the Society of Gynecologic Oncologists separate recommendations for HPV vaccines as well as 3) a consultant to the World Health Organization (WHO), developing their modules on the immunologic basis of HPV vaccines, and harmonizing with current cervical cancer screening. He has served on the board of directors of SGO and currently serves on the ASCCP Executive Council.